GPGrossPatternRESEARCH SYSTEM
SEC CHECK STALE
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Jun 30, 2015

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-15-000083Insurance
Cash30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.cash

$733.8M · CORE · VALID

Policy-benefit growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.insurance.policy_benefits

13.32% · OPTIONAL · NOT_ENOUGH_HISTORY

Net-income growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.net_income

125.47% · CORE · NOT_ENOUGH_HISTORY

Premium growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.insurance.premiums

10.02% · CORE · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-34.24% · CORE · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Increased
Previous
$293.8M
Current
$733.8M
Delta
$440.1M
Claims Growth Increased
Previous
-8.67%
Current
13.32%
Delta
21.98%
Premium Growth Increased
Previous
-4.56%
Current
10.02%
Delta
14.57%
Revenue Growth Decreased
Previous
-8.20%
Current
-34.24%
Delta
-26.04%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.